Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 402

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 402
---
     |                -15 |     |     $(8) |
| Financing activities            |     |              7,778 |     |   $6,921 |

Net cash used in operating activities for the three months ended March 31, 2025 and 2024 was $7.8 million and $6.9 million, respectively, consisting primarily of the operating loss for the respective period. Net cash used in investing activities for the three months ended March 31, 2025 and 2024 was $15 thousand and $8 thousand, respectively. It consisted exclusively of purchases of property and equipment. Net cash provided by financing activities for the three months ended March 31, 2025 and 2024 was $7.8 million and $6.9 million, respectively, consisting exclusively of cash transferred to the Company from parent based on Company cash needs for operating and investing activities. Parent company managed our cash and financing arrangements prior to the completion of the separation.

228

TABLE OF CONTENTS

|                                 |     | Year Ended December 31, 
                    2024 |     |            2023 |     |              |
|:--------------------------------|:----|------------------------:|:----|----------------:|:----|-------------:|
|                                 |     |               Successor |     |       Successor |     |  Predecessor |
| (Dollars in thousands)          |     |            January 1 to 
             December 31 |     | September 28 to 
     December 31 |     | January 1 to 
 September 27 |
| Net cash provided by (used in): |     |                         |     |                 |     |              |
| Operating activities            |     |               $(24,693) |     |        $(4,022) |     |    $(17,359) |
| Investing activities            |     |                    -570 |     |              $— |     |       $(882) |
| Financing activities            |     |                  25,263 |     |          $4,022 |     |      $20,166 |

Net cash used in operating activities for the year ended December 31, 2024 (Successor), and for the periods from January 1, 2023 to September 27, 2023 (Predecessor) and September 28, 2023 to December 31, 2023 (Successor) was $24.7 million, $17.4 million, and